Cargando…

Lifestyle Intervention Randomized Controlled Trial for Age-Related Macular Degeneration (AMD-Life): Study Design

Age-related macular degeneration (AMD) has a strong genetic basis, but environmental factors such as smoking and a healthy diet can decrease the genetic fate by up to 50%. Current guidelines for clinical management include recommendations for a healthy lifestyle and antioxidant supplementation. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: de Koning-Backus, Alexandra P. M., Kiefte-de Jong, Jessica C., van Rooij, Jeroen G. J., Uitterlinden, André G., Voortman, Trudy G., Meester-Smoor, Magda A., Klaver, Caroline C. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9920008/
https://www.ncbi.nlm.nih.gov/pubmed/36771309
http://dx.doi.org/10.3390/nu15030602
_version_ 1784886964442365952
author de Koning-Backus, Alexandra P. M.
Kiefte-de Jong, Jessica C.
van Rooij, Jeroen G. J.
Uitterlinden, André G.
Voortman, Trudy G.
Meester-Smoor, Magda A.
Klaver, Caroline C. W.
author_facet de Koning-Backus, Alexandra P. M.
Kiefte-de Jong, Jessica C.
van Rooij, Jeroen G. J.
Uitterlinden, André G.
Voortman, Trudy G.
Meester-Smoor, Magda A.
Klaver, Caroline C. W.
author_sort de Koning-Backus, Alexandra P. M.
collection PubMed
description Age-related macular degeneration (AMD) has a strong genetic basis, but environmental factors such as smoking and a healthy diet can decrease the genetic fate by up to 50%. Current guidelines for clinical management include recommendations for a healthy lifestyle and antioxidant supplementation. However, many ophthalmologists do not inform their patients of this AMD-beneficial lifestyle. An important reason is the lack of trust that transition of lifestyle will be feasible in persons of advanced age and lack of methodology to measure lifestyle or its biological effects. To address these issues, we set up the lifestyle intervention study AMD-Life. It aims to investigate whether personalized risk-profiling (including genetic testing) and/or additional coaching can motivate patients to change their lifestyle. It also explores which biomarkers best reflect lifestyle change beneficial for AMD. The first year is a three-arm, self-contained open-label randomized clinical trial. A total of 150 AMD patients aged 55–85 years were randomized into three arms: (A) merely standard recommendations; (B) A conditions plus personalized risk profiling based on genetics and lifestyle, (C) B conditions plus coaching. The second year tests sustainability of lifestyle changes without active intervention. AMD-Life can provide further insight into the relevance of these interventions for the clinical management of AMD.
format Online
Article
Text
id pubmed-9920008
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99200082023-02-12 Lifestyle Intervention Randomized Controlled Trial for Age-Related Macular Degeneration (AMD-Life): Study Design de Koning-Backus, Alexandra P. M. Kiefte-de Jong, Jessica C. van Rooij, Jeroen G. J. Uitterlinden, André G. Voortman, Trudy G. Meester-Smoor, Magda A. Klaver, Caroline C. W. Nutrients Article Age-related macular degeneration (AMD) has a strong genetic basis, but environmental factors such as smoking and a healthy diet can decrease the genetic fate by up to 50%. Current guidelines for clinical management include recommendations for a healthy lifestyle and antioxidant supplementation. However, many ophthalmologists do not inform their patients of this AMD-beneficial lifestyle. An important reason is the lack of trust that transition of lifestyle will be feasible in persons of advanced age and lack of methodology to measure lifestyle or its biological effects. To address these issues, we set up the lifestyle intervention study AMD-Life. It aims to investigate whether personalized risk-profiling (including genetic testing) and/or additional coaching can motivate patients to change their lifestyle. It also explores which biomarkers best reflect lifestyle change beneficial for AMD. The first year is a three-arm, self-contained open-label randomized clinical trial. A total of 150 AMD patients aged 55–85 years were randomized into three arms: (A) merely standard recommendations; (B) A conditions plus personalized risk profiling based on genetics and lifestyle, (C) B conditions plus coaching. The second year tests sustainability of lifestyle changes without active intervention. AMD-Life can provide further insight into the relevance of these interventions for the clinical management of AMD. MDPI 2023-01-24 /pmc/articles/PMC9920008/ /pubmed/36771309 http://dx.doi.org/10.3390/nu15030602 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
de Koning-Backus, Alexandra P. M.
Kiefte-de Jong, Jessica C.
van Rooij, Jeroen G. J.
Uitterlinden, André G.
Voortman, Trudy G.
Meester-Smoor, Magda A.
Klaver, Caroline C. W.
Lifestyle Intervention Randomized Controlled Trial for Age-Related Macular Degeneration (AMD-Life): Study Design
title Lifestyle Intervention Randomized Controlled Trial for Age-Related Macular Degeneration (AMD-Life): Study Design
title_full Lifestyle Intervention Randomized Controlled Trial for Age-Related Macular Degeneration (AMD-Life): Study Design
title_fullStr Lifestyle Intervention Randomized Controlled Trial for Age-Related Macular Degeneration (AMD-Life): Study Design
title_full_unstemmed Lifestyle Intervention Randomized Controlled Trial for Age-Related Macular Degeneration (AMD-Life): Study Design
title_short Lifestyle Intervention Randomized Controlled Trial for Age-Related Macular Degeneration (AMD-Life): Study Design
title_sort lifestyle intervention randomized controlled trial for age-related macular degeneration (amd-life): study design
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9920008/
https://www.ncbi.nlm.nih.gov/pubmed/36771309
http://dx.doi.org/10.3390/nu15030602
work_keys_str_mv AT dekoningbackusalexandrapm lifestyleinterventionrandomizedcontrolledtrialforagerelatedmaculardegenerationamdlifestudydesign
AT kieftedejongjessicac lifestyleinterventionrandomizedcontrolledtrialforagerelatedmaculardegenerationamdlifestudydesign
AT vanrooijjeroengj lifestyleinterventionrandomizedcontrolledtrialforagerelatedmaculardegenerationamdlifestudydesign
AT lifestyleinterventionrandomizedcontrolledtrialforagerelatedmaculardegenerationamdlifestudydesign
AT uitterlindenandreg lifestyleinterventionrandomizedcontrolledtrialforagerelatedmaculardegenerationamdlifestudydesign
AT voortmantrudyg lifestyleinterventionrandomizedcontrolledtrialforagerelatedmaculardegenerationamdlifestudydesign
AT meestersmoormagdaa lifestyleinterventionrandomizedcontrolledtrialforagerelatedmaculardegenerationamdlifestudydesign
AT klavercarolinecw lifestyleinterventionrandomizedcontrolledtrialforagerelatedmaculardegenerationamdlifestudydesign